Genmab Regains Rights to HuMax-TAC

Genmab regains rights to HuMax-TAC                                              

Summary: Genmab has regained all rights to HuMax-TAC from Merck Serono S.A.     

Copenhagen, Denmark; August 2, 2007 - Genmab A/S (OMX: GEN) announced today it  
has regained all rights to the HuMax-TAC(TM) antibody from Merck Serono         
following a portfolio review by Merck Serono. Worldwide rights to HuMax-TAC were
previously licensed to Merck Serono in May 2005.  Regaining the rights to       
HuMax-TAC will not influence Genmab's financial guidance for 2007.              

“Now that we have regained rights to the HuMax-TAC program, Genmab will review  
the program internally to decide on future plans,” said Lisa N. Drakeman, Ph.D.,
Chief Executive Officer of Genmab.                                              

About Genmab A/S                                                                
Genmab A/S is a biotechnology company that creates and develops human antibodies
for the treatment of life-threatening and debilitating diseases. Genmab has     
numerous products in development to treat cancer, infectious disease, rheumatoid
arthritis and other inflammatory conditions, and intends to continue assembling 
a broad portfolio of new therapeutic products. In addition, Genmab has developed
UniBody(TM), a new proprietary technology that creates a stable, smaller        
antibody format.  Genmab has operations in Europe and the US. For more          
information about Genmab, visit www.genmab.com.                                 

This press release contains forward looking statements. The words “believe”,    
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify    
forward looking statements. Actual results or performance may differ materially 
from any future results or performance expressed or implied by such statements. 
The important factors that could cause our actual results or performance to     
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical   
trials including unforeseen safety issues, uncertainties related to product     
manufacturing, the lack of market acceptance of our products, our inability to  
manage growth, the competitive environment in relation to our business area and 
markets, our inability to attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents and proprietary rights,   
our relationships with affiliated entities, changes and developments in         
technology which may render our products obsolete, and other factors. Genmab is 
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to      
actual results, unless this is required by law.                                 

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);  
HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);
HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab A/S.                

Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M: 
+45 25 27 47 13, E: hth@genmab.com                                              
                                                                                
Stock Exchange Release no. 33/2007                                              

###